Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa + chemotherapy in Stage IV NSCLC
NCT03840915Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Apr 2019
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 3
01
Overview
A Phase 2 trial of bintrafusp alfa in non-small cell lung cancer (NSCLC), sponsored by EMD Serono. Started Apr 2019; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03840915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840915.